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Abstract 
Recent reports have suggested that women undergoing mastectomy, instead of wide local excision (WLE) for Stage I 
and II breast cancers have poorer overall survival. This is particularly important in our setting where mastectomy rates 
are high. In this study, we evaluated the trends in mastectomy and WLE over a 10-year period at a single institute, 
identified factors more common among women who underwent mastectomy and specifically examined the effect of 
surgery on outcome. Retrospective review was performed of 2244 women who underwent curative surgery for non-
metastatic breast cancer at our institute from 1st January 2001 to 31st December 2010. Mastectomy rates remained 
high over the 10 years, ranging from 43 to 59 %. Older women, those with symptoms, larger tumours and clinical 
nodal involvement were more likely to receive mastectomy (P < 0.05). The type of surgery (mastectomy or WLE) did 
not affect survival in women with ductal carcinoma-in situ, while women with invasive cancer appeared to survive 
longer when treated with WLE (P < 0.01). Surgery type was not an independent predictor of overall survival and the 
survival advantage with WLE did not remain after adjusting for age, implying that the effect on survival had been con-
founded by the fact that older women tended to undergo mastectomy. Mastectomy remains common among our 
local women, with further studies being needed to evaluate factors involved in decision-making. Older women and 
those with significant co-morbidities were more likely to undergo mastectomy and this contributed to an apparent 
survival advantage following WLE.
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Background
Wide local excision (WLE) was widely accepted as an 
alternative to total mastectomy after large studies showed 
that the less radical resection produced superior cos-
mesis without compromising long-term survival (Fisher 
et al. 2002; Veronesi et al. 1981). Greater sub-specialisa-
tion, coupled with growing affluence and an increase in 
small screen-detected tumours, has led to more women 
receiving WLE (Albain et  al. 1996). Wide local excision 
accounts for 60–70 % of surgeries performed in women 
with early stage breast cancer in the developed countries, 
where women tend to place greater emphasis on body 
image and sexuality, are more aware of the available 
treatment options and are more involved in the decision-
making (Agarwal et al. 2014; Lazovich et al. 1999). Neo-
adjuvant chemotherapy, originally used to downstage 
inoperable tumours, has also been employed to increase 
WLE rates (Fisher et al. 1997).
Mastectomy rates have remained high in Singapore and 
many women continue to choose mastectomy over WLE. 
A recent study from another local institute reported that 
70  % of their patients treated between 2001 and 2010 
underwent mastectomy (Sim et al. 2014). Our high mas-
tectomy rates seem contrary to the trend in many other 
developed countries and have persisted despite growing 
affluence, high adult literacy rates, well-publicised breast 
cancer awareness campaigns and a national breast cancer 
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screening program. But although WLE achieves equiva-
lent long-term outcomes through less extensive and dis-
figuring surgery, it entails the need for post-operative 
irradiation of the remnant breast and this factors into the 
choice for WLE. Women with less comprehensive health 
insurance coverage or who stay a considerable distance 
away from a facility that offers radiation treatment were 
reportedly less likely to undergo WLE (Nattinger et  al. 
1992; Chagpar et  al. 2006). Such socioeconomic factors 
may not influence decision-making in our local setting 
to the same extent since government healthcare schemes 
subsidise a significant portion of the treatment costs 
and accessibility to radiation facilities is not an issue in 
Singapore. Even so, with our co-payment scheme, WLE 
and radiation therapy will cost about double that a mas-
tectomy and many women are also deterred by the daily 
treatment sessions required. From an oncological stand-
point, this prevalence of mastectomy matters little since 
long-term survival following both mastectomy and WLE 
are similar (Fisher et al. 2002; Veronesi et al. 2002). How-
ever, recent reports have suggested that mastectomy is 
in fact associated with poorer survival among women 
with Stage I and II breast cancers (Agarwal et  al. 2014; 
Hwang et al. 2013). Given that a significant proportion of 
our local women who are eligible for WLE opt for mas-
tectomy instead, it would be important to determine 
whether WLE does indeed confer a survival advantage.
The primary objectives of this study were to evalu-
ate the trend in the types of surgery (mastectomy versus 
WLE) performed at our institute over a 10-year period 
and to determine whether the type of surgery affects the 
clinical outcome, in terms of overall survival and disease 
recurrence. In addition, we also examined the factors 
more common among women treated with mastectomy 
and sought to identify patient and disease factors that 
may have contributed to the surgery trends over the 
years.
Methods
A retrospective review was performed of 2244 women 
who underwent curative breast cancer surgery, includ-
ing mastectomy, mastectomy and immediate breast 
reconstruction (IBR) and wide local excision (WLE), 
at our institute from 1st January 2001 to 31st Decem-
ber 2010. This study has Ethics Committee approval 
(DSRB2010/00360). Male patients, those with metastatic 
disease undergoing palliative mastectomy and those who 
did not receive treatment at our institute after the initial 
diagnosis were excluded.
The option of WLE was offered to all eligible women, 
such as those with small tumours in relation to the breast 
volume, without contraindications or objections to post-
operative radiation therapy; those with multicentric or 
multifocal tumours, or tumours close to the nipple are-
olar complex were considered on a case-by-case basis. 
Some surgeons recommend mastectomy for invasive 
lobular carcinoma because of the more frequent associa-
tion with multifocal disease, while others include breast 
magnetic resonance imaging (MRI) in the pre-operative 
work-up before proceeding with WLE. Other tumour 
factors do not affect decision-making. Several other fac-
tors, such as advanced age, pre-existing co-morbidities, 
poor family and social support, however, influence the 
choice of surgery. Immediate breast reconstruction 
with an autologous flap was often offered as an option 
to women below 60 years of age without significant co-
morbidities, and was only performed together with a 
mastectomy. The more complex oncoplastic techniques 
now practiced in many centres and reconstruction using 
breast implants were not performed during this period.
Whole breast irradiation was routinely offered to all 
women after WLE. A total dose of 50 Gy, with an addi-
tional boost of 10  Gy to the tumour bed, was adminis-
trated in fractions of 2 Gy over a period of 6 weeks, and 
has been the standard of care since year 2000. In 2010, a 
hyperfractionated regimen (42.5 Gy in 16 fractions) was 
also offered, mostly to women with node-negative dis-
ease after reports of efficacy (Whelan et al. 2010). Post-
mastectomy radiation was recommended in women 
with tumours larger than 5 cm, pre-menopausal women 
with nodal involvement and in all women with N2 (4 or 
more nodes) involvement. The benefit of radiation in 
post-menopausal women with N1 disease is still pend-
ing results of the SUPREMO trial, and was discussed 
on a case-by-case basis. An additional boost of 10 Gy to 
the tumour bed was routinely given, and a higher dose 
of 16  Gy would be considered if there were concerns 
about residual disease post-resection. A 3-field tech-
nique, which included the whole breast or chest wall as 
well as the supraclavicular fossa, was used when there 
was nodal involvement, and a 2-field technique was used 
post-WLE for node-negative disease. Systemic treatment 
recommendations were in accordance with the current 
NCCN guidelines; hormonal therapy was recommended 
for hormone-responsive tumours and trastuzumab for 
HER2-positive tumours larger than T1b. Chemotherapy, 
commonly anthracycline and/or taxane-based, was rec-
ommended for node-positive disease and for node-neg-
ative tumours larger than T1c. Oncotype DX assay was 
discussed on an individual basis.
Data was collected from the clinical records and 
included demographic data, clinical presentation, the 
type of surgery performed and standard pathological and 
outcome parameters. Surgery type was correlated with 
patient demographics and standard clinicopathological 
parameters using the Chi-squared test, t test and one-way 
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ANOVA as appropriate. Univariate analyses were per-
formed with GraphPadPrism version 6 (GraphPad soft-
ware Inc., San Diego, CA, USA). Logistic regression was 
used to identify independent risk factors associated with 
mastectomy and disease recurrence, and was carried 
out using the Stata package release 11.0 (Stata Corpora-
tion, 4905 Lakeway Drive, College Station, Texas 77845, 
USA). A full model was first created to include all poten-
tially important explanatory variables. At each step, the 
variable with the smallest contribution to the model 
was removed, until a final backward stepwise model was 
obtained. Linear regression analysis was applied to study 
the trends in surgery, patient age, tumour size and dis-
ease stage, over the surgical years. Kaplan–Meier sur-
vival curves were calculated using death as the endpoint. 
Overall survival between those treated with mastectomy 
versus those treated with WLE was compared using a log 
rank test. Multivariable cox proportional hazard regres-
sion modeling was performed to examine the effect of 
the type of surgery on overall survival after controlling 
for age, tumour size and ER status, nodal status, disease 
recurrence and systemic treatment. Adjusted survival 
curves were then calculated and plotted based on the 
multivariable cox regression models generated. A 2-tailed 
P value test was used in all analyses and a P value of less 
than 0.05 was considered statistically significant.
Results
Patient and tumour characteristics are detailed in 
Table 1. A total of 2244 women with operable breast can-
cer underwent curative surgery at our institute from 2001 
to 2010. More than half the women (1312 of 2244, 58 %) 
were treated with mastectomy, and of these, 146 women 
(11.1  %) underwent reconstruction at the same setting. 
Median age at diagnosis was 54  years (ranging from 23 
to 94 years of age) and only 8.8 % of women (198 of 2244) 
were younger than 40  years of age. Three hundred and 
thirty-four women (14.9  %) were diagnosed with ductal 
carcinoma-in situ (DCIS), 676 (30.1 %) with Stage I, 762 
(34.0 %) with Stage II and 472 (21.0 %) with Stage III dis-
ease. Over the median follow-up period of 90  months 
(ranging from 2 to 167  months), 146 women developed 
locoregional recurrence, and distant disease was found 
concurrently or subsequently in 80 of them. Distant dis-
ease recurrence in the absence of locoregional disease, 
developed in 194 women and 338 women died during the 
follow-up period.
While the absolute numbers of surgeries performed 
at our institute increased steadily over the 10-year study 
period, the proportion of mastectomies relative to WLE 
did not change significantly with the surgical years 
(Fig.  1a). There was an initial drop in the rate of mas-
tectomies (without reconstruction) from 62  % in 2001 
to 44  % in 2003, coinciding with the implementation of 
nationwide breast cancer screening in 2002, but thereaf-
ter, the mastectomy rate varied from between 43 to 59 % 
and averaged at 53 % over the subsequent years (P = 0.54, 
β = 0.49 ± 0.76). More than half the women with Stage I 
and II cancers underwent mastectomy and there was no 
declining trend over the years (P = 0.48, β = 0.73 ± 0.99) 
(Fig.  1b). This could not be attributed to more women 
opting for IBR, which accounted for only about 7 % of all 
mastectomies performed (P = 0.14, β = 0.73 ± 0.45). We 
did, however, observe a more than two-fold increase in 
IBR rates in the last 2 years, from 7 to 17 %; this increase 
was largely among women with Stage III disease (Fig. 1a, 
b).
Age and existing co-morbidities correlated strongly 
with the type of surgery received. Older women (P < 0.01) 
with major co-morbidities (P  <  0.01), implied by higher 
ASA scores were more likely to undergo mastectomy, as 
were those who had presented with symptoms (rather 
than with screen-detected tumours) (P < 0.01, OR 2.71, 
95 % CI 2.22–3.31) (Table 1). Consistent with tumour size 
being a major consideration for WLE, women treated 
with mastectomy had larger tumours (P < 0.01, OR 10.48, 
95 % CI 0.05–0.17) and were more likely to have a pre-
operative diagnosis of invasive carcinoma (P < 0.01, OR 
1.88, 95 % CI 1.53–2.30), particularly that of invasive lob-
ular carcinoma (P  <  0.01, OR 2.19, 95  % CI 1.35–3.56). 
Women who had received neoadjuvant chemotherapy 
were more also likely to undergo mastectomy, regard-
less of the degree of tumour response (P < 0.01, OR 5.39, 
95 % CI 3.00–9.70). The observed association with nodal 
involvement, negative tumour ER status and tumour 
grade was due to a correlation with larger tumours 
(P < 0.01) (Table 2). Only the age at diagnosis, mode of 
presentation and disease stage remained independently 
associated mastectomy on multivariate analysis (P < 0.05) 
(Table 3).
We next examined the contribution of patient age 
and disease stage to the persistently high mastectomy 
rates. Mean age at diagnosis ranged from between 51 
to 58 years of age (median age from 51 to 59 years), and 
although there seemed to be a gradual increase in the 
age at diagnosis over the years, this was not statistically 
significant (P = 0.08, β = 0.22 ± 0.11) (Fig. 2a). Women 
older than 70  years of age consistently accounted for 
12–19  % of cancers diagnosed each year (P  =  0.81). 
Likewise, women younger than 40  years also accounted 
for <10  % of the cancers diagnosed each year. Tumour 
size remained similar over the years as well (P  =  0.85, 
β  =  −0.01  ±  0.03 and P  =  0.58, β  =  −0.23  ±  0.39, 
respectively) (Fig.  2b); mean tumour size at presenta-
tion ranged from 2.47  ±  0.12 to 3.52  ±  1.93  cm and 
median size was 2.75 cm (ranging from 1.0 to 20.0 cm). 
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Table 1 Correlation analyses of the type of surgery and standard clinicopathological parameters (n = 2244)
Mastectomy (n = 1312) Wide excision (n = 932) P value
Median age 55 (23–94) 51 (24–90) <0.01
Menstrual status 0.01
 Pre-menopausal 945 446
 Post-menopausal 815 482
Ethnicity 0.06
 Chinese 1064 748
 Malay 120 78
 Indians 59 65
 Others 69 41
Presentation <0.01
 Screen detected 219 324
 Symptomatic 1067 582
Median clinical tumour size (cm) 3.0 (0.5–20) 2.0 (0.5–6.0) <0.01
Clinically palpable axillary nodes <0.01
 Yes 149 26
 No 1141 896
Pre-operative diagnosis <0.01
 Invasive CA 1092 673
 DCIS 218 252
 Atypia 2 7
Neoadjuvant chemotherapy <0.01
 Yes 93 13
 No 1219 919
Median pathological tumour size (mm) 25 (1–210) 16 (1–70) <0.01
Tumour histology <0.01
 DCIS 165 221
 IDC 1029 655
 ILC 76 22
 Medullary CA 3 5
 Mucinous CA 16 13
 Papillary CA 3 7
 Others 19 5
Tumour grade 0.09
 1 169 128
 2 501 313
 3 451 265
ER status <0.01
 Positive 847 621
 Negative 394 209
PR status 0.02
 Positive 618 456
 Negative 621 373
Nodal status <0.01
 Positive 602 299
 Negative 575 502
Disease stage <0.01
 DCIS 135 199
 I 311 365
 II 473 289
 III 393 79
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Only about 8  % of tumours diagnosed each year were 
larger than 5  cm. Mastectomy was performed in 510 
of the 1263 women (40.4  %) younger than 70  years of 
age with tumours smaller than 2  cm. There was no sig-
nificant change in the disease stage at presentation 
(P = 0.07, β = 0.51 ± 0.24, P = 0.52, β = −0.27 ± 0.41 
and P = 0.51, β = −0.24 ± 0.35 for DCIS, Stage I and II 
and Stage III disease, respectively) (Fig. 2c). Close to two-
thirds of women presented with Stage I and II disease, up 
to 19 % presented with DCIS and about 20 % presented 
with advanced disease.
Next, we evaluated the impact of the type of surgery 
on clinical outcome. Among women with DCIS, overall 
survival was similar regardless of whether a mastectomy 
or WLE was performed (Fig.  3a). Wide local excision 
appeared to confer a statistically significant survival 
a Information available only from 2006 onwards
Table 1 continued
Mastectomy (n = 1312) Wide excision (n = 932) P value
ASA scorea <0.01
 1 81 62
 2 454 286
 3 87 28
Fig. 1 a The proportion of surgeries performed at our institute by 
surgical year. b The proportion of surgeries performed in women with 
Stage I and II cancers at our institute by surgical year
Table 2 Correlation of  tumour size with  tumour grade 
and ER status (n = 2757)
Parameter Median tumour size (mm) P value
Nodal status <0.01
 Positive 28 (1–210)
 Negative 18 (1–125)
Tumour grade <0.01
 1 15 (1–140)
 2 20 (1–150)
 3 25 (1–210)
ER status <0.01
 Positive 20 (1–140)
 Negative 25 (1–210)
Table 3 Logistic regression model of  the type of  surgery 
received for  standard clinicopathological parameters 
(n = 1042)
a Refers to whether tumours were symptomatic at presentation or were screen-
detected
Parameter Odds ratio SE P value 95 % CI
Age at diagnosis 1.04 0.01 <0.01 1.02–1.05
ASA score 1.14 0.15 0.31 0.88–1.49
Clinical presentationa 2.07 0.34 <0.01 1.50–2.84
Clinical tumour size 7.50 4.62 <0.01 2.24–25.11
Clinically palpable nodes 8.19 5.13 <0.01 2.41–27.92
Pre-operative biopsy 1.19 0.21 0.33 0.84–1.67
ER status 0.78 0.12 0.11 0.57–1.06
Neoadjuvant chemotherapy 1.68 0.74 0.24 0.71–3.98
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advantage in women with invasive cancer (P  <  0.01, 
HR 1.98, 95  % CI 1.49–2.33) (Fig.  3b), and this was 
significant even when Stage III disease was excluded 
(P =  0.03, HR 1.44, 95  % CI 1.04–1.99) (Fig.  3c). Sur-
gery type was no longer significant when included in 
a multivariate model (P  =  0.95) (Table  4), where age, 
tumour size and disease recurrence emerged as inde-
pendent predictors of survival (P  <  0.05), and the sur-
vival difference was no longer present after adjusting 
for age at diagnosis (Fig.  3d). We separately analysed 
node-negative Stage I and II cancers and again did not 
find a difference between survival after a mastectomy 
or a WLE (Fig. 3e). Wide local excision was associated 
with a higher local recurrence rate (P = 0.01, OR 1.89, 
95 % CI 0.33–0.86) (Table 5a) but not distant recurrence 
(P  =  0.44), which was instead predicted by unfavour-
able tumour characteristics such as larger tumour size, 
nodal involvement, ER-negativity, and local recurrence 
(P < 0.05) (Table 5b).
Discussion
In our study, we observed that older women tended to 
undergo mastectomy; 19  % of those who had a mastec-
tomy were older than 70 years of age as compared to 8 % 
of those who had a WLE. We were unable to conclude 
whether this was a preference on the part of the patient or 
the surgeon but from our experience, older women often 
prioritise a shorter treatment course over post-operative 
cosmesis and would rather avoid a repeat operation and 
daily post-operative radiation sessions. Financial costs 
may also be a contributing factor. Surgeons may also be 
more inclined towards mastectomy in older women, par-
ticularly those with significant co-morbidities who could 
have a higher risk of potential morbidity from additional 
surgery and radiation treatments. Even so, as many as 
40  % of our women younger than 70  years of age with 
tumours smaller than 2  cm underwent mastectomy, 
instead of WLE. This may seem a relatively high propor-
tion, but Asian women generally have smaller breast vol-
umes and a 2 cm tumour may be too large or too close 
to the nipple areolar complex for WLE. Median tumour 
size in our study was 2.1  cm, and was larger than most 
tumours in the studies where WLE was found superior 
to mastectomy (Agarwal et al. 2014; Hwang et al. 2013). 
Furthermore, many women opt for mastectomy rather 
than take up neoadjuvant chemotherapy to downsize a 
tumour deemed too large for breast conservation. The 
tendency for women with symptoms to undergo mastec-
tomy may reflect differences in the attitudes and psyche 
of women presenting to the clinics. Women with symp-
toms often seek medical attention because they suspect 
a cancer and often seem to assume that mastectomy 
would be offered once the diagnosis is confirmed. On the 
other hand, women attending breast screening are often 
unprepared for a cancer diagnosis and tend to opt for 
less extensive surgery. Regardless, our study suggests that 
many women eligible for WLE undergo a mastectomy 
instead.
Some centres in the West have reported an increase 
in mastectomies in recent years, citing the more fre-
quent use of pre-operative magnetic resonance imag-
ing (MRI) that has increased the detection of additional 
Fig. 2 a Mean patient age (years) by surgical year. b Mean clinical 
tumour size (cm) by surgical year. c Disease stage at presentation by 
surgical year
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Fig. 3 a Kaplan and Meier curves of 10-year overall survival stratifying patients with DCIS by the type of surgery received (n = 334). b Kaplan and 
Meier curves of 10-year survival stratifying patients with Stage I to III disease by the type of surgery received (n = 1910). c Kaplan and Meier curves 
of 10-year overall survival stratifying patients with Stage I and II disease by the type of surgery received (n = 1438). d Survival curves of 10-year 
survival stratifying patients with Stage I and II disease by the type of surgery received, adjusted for age at time of diagnosis (n = 1429). e Survival 
curves of 10-year survival stratifying patients with node negative Stage I and II disease by the type of surgery received, adjusted for age at time of 
diagnosis (n = 1040)
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occult tumour foci elsewhere in the breast (Katipamula 
et al. 2009). This was unlikely to have contributed to our 
high mastectomy rates, since breast MRI is limited to 
women with invasive lobular carcinomas who are keen 
for WLE. Growing preference for breast reconstruc-
tion may also have contributed to this increase, particu-
larly among younger women who find the more natural 
appearing post-operative body image especially appeal-
ing (Alderman et  al. 2008). Furthermore, though breast 
conservation is not contraindicated in young women, 
surgeons have been known to recommend mastectomy 
more strongly because of reportedly higher local fail-
ure rates after WLE (Voogd et  al. 2001; de Bock et  al. 
2006). Reconstruction accounted for less than a quar-
ter of our cases and had not increased much except in 
the last 2  years, making it unlikely to have accounted 
for the persistently high mastectomy rates. A more 
advanced age and disease stage at diagnosis were also 
unlikely contributing factors. The average age at diag-
nosis had not increased significantly over the years and 
was in fact similar to that reported in the Surveillance, 
Epidemiology, and End Results data. Significantly, the 
numbers of women older than 70 years or younger than 
40 years, who more often received mastectomy, had not 
increase. Similar numbers of women remained eligible 
for WLE and <10 % of tumours were staged as T3 or T4 
at presentation.
In keeping with published reports, local recurrence 
was two-fold higher following WLE, even with standard 
radiation doses (Darby et al. 2011). Despite a correlation 
between local recurrence and distant relapse, we did not 
find WLE to adversely affect long-term survival, reaf-
firming findings from previous studies (Fisher et al. 2002; 
Veronesi et al. 1981; Blichert-Toft et al. 2008). Our obser-
vation that 70  % of distant recurrences occurred in the 
absence of locoregional disease, while only 45 % of those 
with locoregional recurrence developed systemic disease, 
supports the postulation that distant disease relapse is 
not necessarily a direct consequence of untreated locore-
gional disease (Le et al. 2002). In fact, locoregional recur-
rences are often isolated and amenable to local therapy, 
and thus may not affect survival (Schmoor et  al. 2000). 
Rather, distant relapse is more likely a manifestation of 
inherent tumour aggressiveness, as evident from the 
association with unfavourable disease factors such as 
larger tumour size, nodal involvement and ER negativity.
Our findings are in direct contrast to two recent studies 
that reported a survival advantage with WLE, even after 
controlling for established prognostic factors such as 
tumour size and nodal status (Agarwal et al. 2014; Hwang 
et al. 2013). We, too, observed a similar survival benefit 
among women who received WLE, but this survival dif-
ference was no longer present after adjusting for patient 
age. This implied that the apparent survival difference 
was due to inherent differences in the women included 
in both groups, and was because women who under-
went mastectomy tended to be older and with more co-
morbidities. Hwang and colleagues found WLE to confer 
a survival advantage even after excluding women who 
received post-mastectomy irradiation (more advanced 
disease), but this could have been confounded by more 
women with node-negative disease undergoing WLE 
(Hwang et  al. 2013). We therefore specifically analysed 
women with node-negative Stage I and II disease, who 
would have either received no radiation after mastectomy 
or a 2-field radiation technique, which did not include 
Table 4 Multivariate analysis cox regression model 
of  overall survival for  mastectomy and  standard clin-
icopathological parameters in  patients diagnosed 
between 2001 and 2010 (n = 1382)
a Chemotherapy, hormonal therapy (and targeted therapy from 2006 onwards)
Parameter Hazard ratio SE P value 95 % CI
Type of surgery received 0.98 0.25 0.95 0.59–1.63
Age at diagnosis 1.08 0.01 <0.01 1.06–1.10
Tumour size 1.02 0.01 0.04 1.00–1.03
ER status 0.64 0.16 0.07 0.39–1.03
Nodal status 1.30 0.33 0.31 0.79–2.15
Disease recurrence 57.29 16.60 <0.01 32.47–101.08
Systemic treatment 
omitteda
0.73 0.33 0.49 0.30–1.78
Table 5 Logistic regression model of  (a) local recurrence 
and  (b) distant recurrence for  type of  surgery received 
and  standard clinicopathological parameters, in  patients 
diagnosed between 2001 and 2010 (n = 1382)
a Systemic therapy includes chemotherapy and hormonal therapy
Parameter Odds ratio SE P value 95 % CI
(a)
 Type of surgery 0.48 0.13 0.01 0.29–0.80
 Age at diagnosis 0.99 0.01 0.49 0.97–1.03
 Tumour size 1.01 0.01 0.14 0.10–1.03
 ER status 0.45 0.12 <0.01 0.27–0.76
 Nodal status 1.49 0.41 0.15 0.87–2.57
 Systemic therapy omitteda 6.02 2.00 <0.01 3.13–11.55
(b)
 Type of surgery 1.20 0.28 0.44 0.76–1.90
 Age at diagnosis 1.00 0.01 0.78 0.99–1.02
 Tumour size 1.03 0.01 <0.01 1.01–1.04
 ER status 0.63 0.14 0.04 0.40–0.99
 Nodal status 1.71 0.39 0.02 1.09–2.68
 Local recurrence 13.15 3.68 <0.01 7.60–22.76
 Systemic therapy omitteda 1.71 0.66 0.17 0.80–3.63
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the level II and III nodes, after WLE. Again, we did not 
observe any survival difference between WLE and mas-
tectomy after adjusting for age, and this strengthens our 
hypothesis that the apparent survival advantage of WLE 
was primarily due to the women being younger and with 
less co-morbidities. This is consistent with our obser-
vation that older women, who also tend to have greater 
co-morbidities (higher ASA scores), were more likely to 
receive mastectomy. Mastectomy is often seen as the bet-
ter option in such poor-risk patients since it avoids the 
need for a repeat surgery and daily radiation treatments. 
This was in fact alluded to in one of the two reports of 
WLE superiority, which showed that women treated with 
WLE had reduced mortality from cardiovascular, cere-
brovascular and chronic respiratory causes (Hwang et al. 
2013). It seems unlikely that the type of operation itself 
would affect mortality, since the surgical risks involved 
are similar and there is no convincing evidence that mas-
tectomy causes greater physiological disturbances or 
long-term health effects. Post-operative recovery is also 
relatively similar and both surgeries are routinely per-
formed as ambulatory procedures at our institute (Ng 
et al. 2014). On the contrary, post-WLE irradiation to the 
left breast may even increase mortality from late onset 
cardiotoxicity (Darby et al. 2013).
Conclusions
Mastectomy rates at our institute have remained high 
over the last 10  years, and cannot be attributed to an 
increased uptake of immediate breast reconstruction, or 
to more advanced age or disease at presentation. Having 
observed that many women eligible for WLE undergo 
mastectomy instead, further studies would provide use-
ful insight into the factors and dynamics that influence 
the decision-making process. Importantly, we found that 
overall survival was similar regardless of the type of sur-
gery performed, and that the apparent survival advantage 
of WLE could be attributed to younger and good-risk 
patients receiving WLE.
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